TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26527417
Drug: A4250 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: A4250 3 mg/day
Study: 26527417
Drug: A4250 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: A4250 1.5 mg twice daily
Study: 26527417
Drug: A4250 0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: A4250 0.1, 0.3, 1, 3, or 10 mg (single administration)
Study: 19094432
Drug: Intravenous remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous remifentanil (0.3 - 0.6 microg/kg per min)
Study: 19094432
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (5 - 10 microg/kg per h)
Study: 15663590
Drug: Live lactobacilli
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live lactobacilli in combination with low dose oestriol (Gynoflor)
Study: 7872940
Drug: Exposure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure treatment in a subgroup of 40 patients
Study: 24796714
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health educational program (90-min every 2 weeks for 3 months)
Study: 24796714
Drug: General information
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: General information about oral health (control group)
Study: 21640779
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever vaccine (YFV) and measles-mumps-rubella (MMR) vaccine given simultaneously
Study: 21640779
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever vaccine (YFV) and measles-mumps-rubella (MMR) vaccine given 30 days apart
Study: 21640779
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever vaccine (YFV) and measles-mumps-rubella (MMR) vaccine
Study: 19120333
Drug: Medium-dose UVA1
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose UVA1 phototherapy
Study: 16829185
Drug: Levosimendan (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (12 microg/kg followed by a continuous infusion of 0.1-0.2 microg/min)
Study: 15054439
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g taurine daily for 8 weeks
Study: 3520132
Drug: Minoxidil, 2.5
Normalized name: Minoxidil, 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minoxidil, 2.5 mg twice daily (n = 12)
Study: 3520132
Drug: Captopril, 25
Normalized name: Captopril, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril, 25 mg twice daily (n = 11)
Study: 31733985
Drug: Inhaler drug
Normalized name: Inspirease Inhaler Drug Delivery Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaler drug education
Study: 31733985
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no inhaler drug education)
Study: 21749847
Drug: Midodrine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine plus standard medical therapy
Study: 20632084
Drug: Fulvestrant 250
Normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant 250 mg/month (approved dose)
Study: 20632084
Drug: Fulvestrant 250
Normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant 250 mg plus loading dose (500 mg on day 0, 250 mg on days 14, 28, and monthly thereafter)
Study: 20632084
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg (high dose)
Study: 18517289
Drug: Paroxetine 10
Normalized name: PARoxetine 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 10 mg
Study: 10548902
Drug: Orlistat 3
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 3 x 120 mg/day
Study: 8527701
Drug: Roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine acetate 150 mg
Study: 2337212
Drug: 0.2 or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 or 0.3 mg/kg diltiazem 60 seconds before laryngoscopy
Study: 28033561
Drug: Aspirin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (10 days of intake)
Study: 28033561
Drug: Aspirin resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin resistance tests (PFA‐200, VerifyNow®, TXB2)
Study: 26273264
Drug: Chlorhexidine (CHX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine (CHX), amoxicillin (AMX) 500 mg, metronidazole (MET) 250 mg
Study: 28463028
Drug: Oral naproxen
Normalized name: naproxen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naproxen
Study: 21435642
Drug: Administration at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration at fixed intervals
Study: 17825135
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol 800 microg
Study: 31183514
Drug: Pertuzumab 840
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab 840 mg intravenous plus trastuzumab and chemotherapy
Study: 22529036
Drug: Neurobehavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neurobehavioral intervention (n = 25), weekly sessions
Study: 22529036
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (n = 13), standard weekly home visits
Study: 20973982
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa 300 μg Q2W or 500 μg Q3W (EDS)
Study: 20973982
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa 150 μg QW (weekly)
Study: 10323115
Drug: Tenoxicam 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 40 mg intravenous injection at induction, followed by 20 mg tablet in the evening of the operation and 20 mg daily from days 2 to 7
Study: 10323115
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 75 mg intramuscular injection at induction, followed by 50 mg tablet 4 to 6 hours after operation and 50 mg three times daily for the next 6 days
Study: 28604089
Drug: 0.9 mL
Normalized name: ethanol 0.9 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mL of 2% lidocaine with epinephrine 1:100,000
Study: 28604089
Drug: 0.9 mL
Normalized name: ethanol 0.9 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mL of 4% articaine with epinephrine 1:100,000
Study: 26493267
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and Carboplatin intercalated with Gefitinib (PCG) - P 175 mg/m², C AUC 5 on day 1, G 250 mg orally on days 2-15 for four cycles followed by G 250 mg orally until progressive disease.
Study: 26493267
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and Carboplatin alone (PC) - same dosing schedule for four cycles only.
Study: 11248662
Drug: Clodronate 800
Normalized name: clodronic acid 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 800 mg daily by mouth
Study: 8996143
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 every 3 weeks plus Cyclophosphamide 750 mg/m2 (CC group, n = 22)
Study: 8996143
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 every 3 weeks plus Paclitaxel 175 mg/m2 over a 3-hour infusion (CP group, n = 24)
Study: 8996143
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus Cyclophosphamide (CC group)
Study: 8490639
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control classes
Study: 24864486
Drug: sylvinite speleoclimatotherapy
Normalized name: Sylvite
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sylvinite speleoclimatotherapy (10 sessions, 60 min each) in addition to conventional pharmacotherapy
Study: 24864486
Drug: traditional medicamental
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: traditional medicamental therapy alone
Study: 23402084
Drug: TAC-Short-term (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC-Short-term (2 mo) low-dose steroid (STER)
Study: 23402084
Drug: Rejection treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rejection treatment
Study: 16248241
Drug: Modified Qingwen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Qingwen Baidu Decoction (MQBD) in addition to conventional therapy (corticosteroid, anti-viral, anti-bacterial, symptomatic and supporting therapy)
Study: 16248241
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (corticosteroid, anti-viral, anti-bacterial, symptomatic and supporting therapy)
Study: 10960643
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 200 microg
Study: 7636057
Drug: Inhaled furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled furosemide (10 mg/body square meters)
Study: 3295623
Drug: Treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm 1
Study: 3295623
Drug: Treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm 2
Study: 335867
Drug: Trimazosin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimazosin (300 and 450 mg daily)
Study: 28699044
Drug: Narrowband UVB
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Narrowband UVB (NB‐UVB) therapy
Study: 20495919
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose capecitabine (CCB 1) 1,250 mg/m² p.o. twice daily for 2 weeks
Study: 20495919
Drug: Dose-intensified capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose-intensified capecitabine (CCB 2) 1,750 mg/m² p.o. twice daily for 1 week
Study: 9370898
Drug: Hydrocortisone 25
Normalized name: hydrocortisone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 25 mg/m2
Study: 9370898
Drug: Hydrocortisone 15
Normalized name: hydrocortisone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 15 mg/m2
Study: 1555625
Drug: SR-verapamil 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR-verapamil 360 mg o.d.
Study: 1555625
Drug: nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 20 mg t.d.s.
Study: 27883209
Drug: Traditional dysphagia
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dysphagia therapy
Study: 30676426
Drug: Combined intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intervention (rTMS + traditional dysphagia therapy)
Study: 28807635
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg (n=183)
Study: 28807635
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg with laser (n=180)
Study: 28807635
Drug: Laser (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser (with optional ranibizumab 0.5 mg after month 6; n=92)
Study: 27039022
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg with laser
Study: 31808278
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg monotherapy
Study: 28807635
Drug: Laser (monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser (monotherapy and combined with ranibizumab from month 6)
Study: 26318715
Drug: RV3-BB vaccine
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RV3-BB vaccine and Placebo
Study: 20461382
Drug: PX-12 (54
Approvals — FDA: no, EMA: no, PMDA: no
Description: PX-12 (54 or 128 mg/m²) administered by 3-hour IV infusion daily for 5 days every 21 days
Study: 20461382
Drug: PX-12 (128
Approvals — FDA: no, EMA: no, PMDA: no
Description: PX-12 (128 mg/m²)
Study: 20461382
Drug: PX-12 (54
Approvals — FDA: no, EMA: no, PMDA: no
Description: PX-12 (54 mg/m²)
Study: 11007235
Drug: Commercial kit
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial kit for antitissue transglutaminase antibodies (INOVA Diagnostics, Inc.)
Study: 11007235
Drug: Antiendomysial antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiendomysial antibody
Study: 11007235
Drug: Antitissue transglutaminase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antitissue transglutaminase antibodies (blind determination)
Study: 8770996
Drug: Cyclosporine (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (treatment duration > or = 24 months)
Study: 8770996
Drug: Cyclosporine (GFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (GFR < or = 50 ml/min/1.73 m2)
Study: 1478285
Drug: Regional isolated
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional isolated perfusion as adjuvant treatment
Study: 31453489
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy group (n=52)
Study: 10883872
Drug: CHX spray
Normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHX spray
Study: 1443446
Drug: Formalinized depot
Normalized name: formalin
DrugBank: Formaldehyde (DB03843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formalinized depot grass allergoid (cumulative pre-seasonal dosage of 46,050 PNU)
Study: 29925930
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rituximab with therapy targeting CD4+ T cells
Study: 27890801
Drug: EUS-guided paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: EUS-guided paclitaxel injection (PTX) plus standard of care (SOC)
Study: 25720672
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 capsules once weekly for 8 weeks
Study: 25720672
Drug: Starch capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch capsules (placebo) once weekly for 8 weeks
Study: 21819556
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 17.5 mg weekly
Study: 21819556
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 2.5 mg/kg daily
Study: 11464310
Drug: Indomethacin 75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 75 mg daily for 3 weeks
Study: 2563616
Drug: Grenz ray
Normalized name: Ray Dol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grenz ray therapy (5 Gy applied on 10 occasions at intervals of 1 week)
Study: 799988
Drug: Imipramine (Tofranil)
Normalized name: imipramine hydrochloride Oral Solution [Tofranil]
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine (Tofranil) added to standard analgesic anti-rheumatic therapy
Study: 27932679
Drug: NSAIDs (ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (ibuprofen 1,200 mg/day)
Study: 16729788
Drug: Montelukast (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (4 mg tablet)
Study: 3093221
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg enoxacin
Study: 3093221
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg enoxacin
Study: 28139405
Drug: Idelalisib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idelalisib (150 mg orally twice daily) in combination with bendamustine and rituximab
Study: 28139405
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with bendamustine and rituximab
Study: 20507568
Drug: Interspinous implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interspinous implant surgery
Study: 18790154
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive treatment for rectal cancer
Study: 16263817
Drug: 4.4 mg
Normalized name: pectin 4.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.4 mg testosterone gel
Study: 16263817
Drug: 8.8 mg
Normalized name: menthol 8.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.8 mg testosterone gel
Study: 16263817
Drug: 13.2 mg
Normalized name: menthol 13.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13.2 mg testosterone gel
Study: 16263817
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg testosterone gel
Study: 16263817
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of testosterone gel
Study: 12684146
Drug: NuvaRing with
Approvals — FDA: no, EMA: no, PMDA: no
Description: NuvaRing with nonoxynol‐9 co-medication
Study: 11027905
Drug: Ketamine 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.50 mg/kg
Study: 8156509
Drug: Continuous hyperthermic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous hyperthermic peritoneal perfusion (CHPP) with 10 micrograms/ml mitomycin C
Study: 3168696
Drug: pH-sensitive enteric-coated
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-sensitive enteric-coated pancreatic enzyme preparation
Study: 3168696
Drug: Conventional enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional enzyme preparations
Study: 30033855
Drug: Daily dysmenorrhea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dysmenorrhea and nonmenstrual pelvic pain impact items
Study: 28138971
Drug: Oral cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabis administration (6.9% [50.4 mg] THC)
Study: 24059116
Drug: rTMS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS treatment for 2 weeks (15 days) combined with selective serotonin reuptake inhibitor (SSRI)
Study: 24059116
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (SSRI) only
Study: 18974308
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (cognitive behavioral therapy + sertraline)
Study: 18974308
Drug: Sertraline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (up to 200 mg per day)
Study: 9032569
Drug: All therapies
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All therapies
Study: 10852274
Drug: i.v. clodronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. clodronate 300 mg daily for 10 consecutive days
Study: 6784264
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active drugs (Propranolol, Atenolol, Metoprolol)
Study: 6784264
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs (including placebo)
Study: 23398944
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d lutein
Study: 21290392
Drug: 940 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 940 nm laser treatment (GR1)
Study: 21290392
Drug: Topical PA
Normalized name: Mega Topical Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical PA agent indocyanine-green followed by 810 nm laser treatment (GR2)
Study: 19118130
Drug: Distributed Constraint-Induced
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distributed Constraint-Induced Therapy (CIT)
Study: 9770738
Drug: Diltiazem (60-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60-90 mg 4 times a day)
Study: 9770738
Drug: Nifedipine (20-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20-30 mg 4 times a day)
Study: 9770738
Drug: Diltiazem (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (single dose)
Study: 3066967
Drug: Nifedipine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (single dose)
Study: 9770738
Drug: Nifedipine (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (long-term treatment)
Study: 9770738
Drug: Diltiazem (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (long-term treatment)
Study: 7885111
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose chemotherapy
Study: 30658935
Drug: PET-driven treatment
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET-driven treatment (ABVD after positive PET2 or BEACOPPescalated after negative PET2)
Study: 30658935
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (BEACOPPescalated for all cycles)
Study: 30658935
Drug: PET-driven treatment
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET-driven treatment (ABVD after positive PET2)
Study: 30658935
Drug: PET-driven treatment
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET-driven treatment